Research programme: alpha synuclein inhibitors- Enterin

Drug Profile

Research programme: alpha synuclein inhibitors- Enterin

Alternative Names: ENT 01; Enterin-01; kenterin

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Enterin
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Constipation

Most Recent Events

  • 03 Feb 2017 Preclinical trials in Constipation in USA (PO) (Enterin pipeline, February 2017)
  • 03 Feb 2017 Enterin plans a phase I/IIa trial for Constipation in USA (NCT03047629)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top